DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Markus Manns - 2 Maggie Fick - 2 Radhika Anilkumar - 2 Josephine Mason - 2 Swedish drugmaker - 1 Pascal Soriot - 1 Alexion - 1 drugmaker - 1
Top related locs:
London Bengaluru China LONDON Swedish China
Top related orgs:
U.S - 2 Union Investment - 2 Thomson - 2 AstraZeneca - 1 UK's - 1 Pfizer - 1 Moderna - 1 GSK - 1

Search resuls for: "Maggie Fick Radhika Anilkumar"


2 mentions found


☆ AstraZeneca Q2 results beat estimates; COVID vaccine sales evaporate
  + stars: | 2023-07-28 | by ( Maggie Fick Radhika Anilkumar | Maggie Fick | Radhika Anilkumar | ) www.reuters.com   time to read: +3 min
SummaryCompanies Q2 sales and earnings beat estimatesReiterates full-year guidanceNo revenue from COVID vaccine in Q2Shares up 3.1% in early tradeCompany is largest drugmaker in ChinaLONDON, July 28 (Reuters) - AstraZeneca (AZN.L) on Friday delivered better-than-expected profits and sales in the second quarter as a strong performance of its blockbuster cancer drugs helped offset the loss of COVID-19 vaccine sales. The Anglo-Swedish drugmaker posted an adjusted profit of $2.15 per share, up 25% and exceeding the $1.98 per share expected in company-compiled consensus estimates. Total revenue in the quarter was $11.4 billion, up 6% and beating company-compiled analyst estimates of $10.97 billion. Excluding COVID medicines, sales in China grew by 7% at constant exchange rates in the quarter, the fourth consecutive quarter of growth on that basis. AstraZeneca is the largest drugmaker in China, which accounted for 13% of last year's revenue.
Persons: Swedish drugmaker, Pascal Soriot, Markus Manns, Alexion, drugmaker, Maggie Fick, Radhika Anilkumar, Nivedita Bhattacharjee, Josephine Mason Organizations: AstraZeneca, UK's, Pfizer, Moderna, U.S, Union Investment, Thomson Locations: China LONDON, Swedish, China, London, Bengaluru
☆ GSK raises 2023 outlook boosted by vaccine, HIV drug sales
  + stars: | 2023-07-26 | by ( Maggie Fick Radhika Anilkumar | Maggie Fick | Radhika Anilkumar | ) www.reuters.com   time to read: +3 min
GSK reckons the spin-off has allowed the company to sharpen its focus on vaccines and infectious diseases and with $7 billion generated by the Haleon spin-off, it can fund deals to bolster a lacklustre drug pipeline. The company also reported an adjusted profit of 38.8 pence per share for the quarter, on sales of about 7.18 billion pounds ($9.26 billion). Analysts were expecting a profit of 34.7 pence per share on sales of about 6.77 billion pounds, according to company-compiled consensus estimates. Sales of Shingrix, the company's top-selling drug, generated 880 million pounds, beating analyst estimates of 872 million pounds. Sales of HIV treatments generated 1.58 billion in the quarter, ahead of the company-compiled consensus of about 1.5 billion pounds in the quarter.
Persons: Zantac, Emma Walmsley, Walmsley, Markus Manns, Dani Saurymper, Maggie Fick, Radhika Anilkumar, Janane Venkatraman, Savio D'Souza, Josephine Mason Organizations: GSK, British, Analysts, U.S, Union Investment, Pacific Asset Management, Thomson Locations: London, Bengaluru
0 next >>
Total: 2